Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma

Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evalua...

Full description

Saved in:

Bibliographic Details
Published in:	Gynecologic oncology Vol. 34; no. 3; p. 395
Main Authors:	Runowicz, C D, Wadler, S, Rodriguez-Rodriguez, L, Litwin, P, Shaves, M, O'Hanlan, K A, Goldberg, G L, Tomaino, C T, Byrnes, R
Format:	Journal Article
Language:	English
Published:	United States 01-09-1989
Subjects:	Adult Aged Antigens, Tumor-Associated, Carbohydrate - analysis Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - therapy Cisplatin - administration & dosage Cisplatin - therapeutic use Combined Modality Therapy - adverse effects Drug Administration Schedule Female Follow-Up Studies Humans Leukocyte Count - drug effects Leukocyte Count - radiation effects Middle Aged Neoplasm Staging Platelet Count - drug effects Platelet Count - radiation effects Prognosis Prospective Studies Radiotherapy Dosage Tomography, X-Ray Computed Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - radiotherapy Uterine Cervical Neoplasms - therapy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 x 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.
ISSN:	0090-8258
DOI:	10.1016/0090-8258(89)90180-7